Lenacapavir is a long-acting injectable pre-exposure prophylaxis (PrEP) medicine used to prevent HIV in people who are HIV-negative. Administered as an injection only twice a year, lenacapavir represents a major breakthrough in HIV prevention by providing highly effective, discreet, and long-lasting protection without the need for daily pills.
- Twice-Yearly Injectable Protection – Lenacapavir provides six months of continuous HIV prevention with a single injection. With only two injections per year, it significantly reduces the burden of frequent dosing and clinic visits, making HIV prevention simpler, more convenient, and easier to sustain.
- Extremely High Effectiveness – Lenacapavir is one of the most effective PrEP options available, offering strong and reliable protection against HIV across diverse populations.
- Improved Adherence – Infrequent dosing greatly improves adherence to PrEP. Lenacapavir eliminates challenges associated with missed doses, forgetfulness, and inconsistent use, ensuring dependable protection over time.
- Reduced Stigma and Greater Privacy – Because it does not require daily medication, lenacapavir helps reduce stigma and the risk of unintended disclosure. Users can protect themselves from HIV discreetly, supporting autonomy, dignity, and confidence.
- User-Friendly and Highly Acceptable – Lenacapavir’s injectable format is well suited for people who prefer not to take pills or who face challenges with daily medication routines. Its long-acting nature makes it especially beneficial for individuals with busy or unpredictable lifestyles.
- Strong Safety and Tolerability – Lenacapavir has demonstrated a favorable safety and tolerability profile, supporting its use for long-term HIV prevention.
- Transformational Impact on HIV Prevention – Lenacapavir has the potential to significantly reduce new HIV infections, particularly in high-burden settings where adherence to daily PrEP remains low. It strengthens combination prevention strategies and accelerates progress toward ending the HIV epidemic.
Advancing Equity in HIV Prevention as Long-acting injectable PrEP with lenacapavir can expand access to effective HIV prevention in low- and middle-income countries, helping close persistent gaps in prevention coverage and reach populations most at risk.
No comment